An activist investor has announced building a significant, active position in Quantum Computing Inc. (QCLS), signaling a strong vote of confidence in the company's future. This presents an opportunity for investors to gain exposure to the high-growth quantum computing sector alongside influential involvement. A separate, high-risk opportunity exists with Capricor Therapeutics (CAPR), a biotech company with a major upcoming catalyst. The stock's value is tied to the FDA's decision on its Duchenne muscular dystrophy drug, Deremyocel, following the company's recent submission of positive trial data. A final FDA decision is targeted for around July of next year, creating a significant binary event for investors.

Capricor Therapeutics (CAPR)

• The podcast begins with a highly bearish and skeptical view of Capricor Therapeutics from the host, Martin Shkreli, followed by the company's official conference call presenting bullish clinical trial results.

• Initial Bearish View (from the host):

  • The host alleges that the company "lied" about their HOPE 3 trial results for their drug, Deremyocel.
  • The primary criticism is that CAPR changed the primary endpoint of their clinical trial.
    • The original endpoint on clinicaltrials.gov was listed as "mean change from baseline" in upper limb function.
    • The company reported results based on "percent slowing of progression," which the host claims is a way to manipulate the data to look more favorable.
  • He questions the statistical significance of the reported 1.2-point improvement on a 42-point scale, stating it "can't be statistically significant" with the number of patients in the trial. He refers to this as "same old capper shenanigans."

• Company's Bullish Presentation:

  • CAPR announced positive top-line results from its pivotal Phase 3 HOPE 3 study for its drug Deremyocel in treating Duchenne muscular dystrophy (DMD).
  • The company claims the trial met its primary and key secondary endpoints with statistical significance.
    • Primary Endpoint (Upper Limb Function): Achieved a 54% slowing of disease progression, which equates to a 1.2-point absolute change. The result was statistically significant with a p-value of 0.029.
    • Key Secondary Endpoint (Cardiac Function - LVEF): Showed a 91% slowing of disease progression with a statistically significant p-value of 0.041.
  • Addressing the Endpoint Controversy: During the Q&A, the CEO explained that "percent change" is a more relevant way to measure function for patients with different baseline levels. Crucially, she also stated that the trial did meet statistical significance on the absolute change as well, with a p-value of 0.05, which she called a "belt and suspenders" win.
  • Regulatory Path:
    • The company previously received a Complete Response Letter (CRL) from the FDA, which is a rejection of their application pending more data.
    • CAPR believes this new, robust data from the HOPE 3 trial directly answers the FDA's concerns.
    • They plan to resubmit their application in response to the CRL and are targeting a PDUFA date (the FDA's decision deadline) around July of the following year, though they hope for an accelerated review.

Takeaways

• High-Risk, High-Reward Biotech Play: This stock presents a classic binary event scenario, where the future price is heavily dependent on an upcoming FDA decision.
• Conflicting Narratives: There is a strong bearish case (from the host) focused on alleged data manipulation and a strong bullish case (from the company) based on officially presented, statistically significant trial results.
• The Key Debate: The central issue is the validity of the trial's primary endpoint. While the company provided a rationale for using "percent change," their claim of also hitting the "absolute change" endpoint (p-value of 0.05) could neutralize the primary bearish argument.
• Upcoming Catalyst: The main event to watch for is the company's resubmission of its Biologics License Application (BLA) and the subsequent FDA review. Any news regarding the FDA's acceptance of the filing or the final PDUFA decision will be a major catalyst for the stock.
• Potential Market: If approved, Deremyocel would target an unmet need, particularly for non-ambulatory Duchenne patients, and could be used alongside other therapies. The company is aiming for a broad label covering both skeletal and cardiac aspects of the disease.

Quantum Computing Inc. (QCLS)

• At the end of the podcast, the host, Martin Shkreli, announced a new personal investment.
• He has "built a position" in QCLS, a publicly traded quantum computing company.
• He stated that he and a partner will be actively involved in "helping the company build the company." He also mentioned he would be interested in a CEO role if legally possible.

Takeaways

• Strong Bullish Signal from Host: The host is not just a passive investor; he has taken a large, active stake with the intention of influencing the company's direction. This is a strong vote of confidence.
• Activist Involvement: Shkreli's involvement could bring significant attention to QCLS and may lead to strategic changes, partnerships, or other value-driving events.
• Sector Exposure: This is an investment in the high-growth, speculative sector of quantum computing. Investors interested in this theme may see this as a signal to investigate QCLS further.